Literature DB >> 23063501

Tissue-type plasminogen activator protects neurons from excitotoxin-induced cell death via activation of the ERK1/2-CREB-ATF3 signaling pathway.

Fang Wu1, Ramiro Echeverry, Jialing Wu, Jie An, Woldeab B Haile, Deborah S Cooper, Marcela Catano, Manuel Yepes.   

Abstract

The release of the serine proteinase tissue-type plasminogen activator (tPA) from cerebral cortical neurons has a neuroprotective effect in the ischemic brain. Because excitotoxicity is a basic mechanism of ischemia-induced cell death, here we investigated the effect of tPA on excitotoxin-induced neuronal death. We report that genetic overexpression of neuronal tPA or treatment with recombinant tPA renders neurons resistant to the harmful effects of an excitotoxic injury in vitro and in vivo. We found that at concentrations found in the ischemic brain, tPA interacts with synaptic but not extrasynaptic NMDARs. This effect is independent of tPA's proteolytic properties and leads to a rapid and transient phosphorylation of the extracellular signal regulated kinases1/2 (ERK1/2), with ERK1/2-mediated activation of the cAMP response element binding protein (CREB) and induction of the neuroprotective CREB-regulated activating transcription factor 3 (Atf3). In line with these observations, Atf3 down-regulation abrogates the protective effect of tPA against excitotoxin-induced neuronal death. Our data indicate that tPA preferentially activates synaptic NMDARs via a plasminogen-independent mechanism turning on a cell signaling pathway that protects neurons from the deleterious effects of excitotoxicity. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23063501      PMCID: PMC3540185          DOI: 10.1016/j.mcn.2012.10.001

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  29 in total

Review 1.  Is CREB a key to neuronal survival?

Authors:  M R Walton; I Dragunow
Journal:  Trends Neurosci       Date:  2000-02       Impact factor: 13.837

2.  Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity.

Authors:  Jose P Lopez-Atalaya; Benoit D Roussel; Denis Levrat; Jérôme Parcq; Olivier Nicole; Yannick Hommet; Karim Benchenane; Hervé Castel; Jérôme Leprince; Denis To Van; Ronan Bureau; Sylvain Rault; Hubert Vaudry; Karl-Uwe Petersen; Jana Sopkova-de Oliveira Santos; Carine Ali; Denis Vivien
Journal:  J Cereb Blood Flow Metab       Date:  2008-03-12       Impact factor: 6.200

3.  Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function.

Authors:  Andre L Samson; Simon T Nevin; David Croucher; Be'eri Niego; Philip B Daniel; Thomas W Weiss; Eliza Moreno; Denis Monard; Daniel A Lawrence; Robert L Medcalf
Journal:  J Neurochem       Date:  2008-09-15       Impact factor: 5.372

4.  Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus.

Authors:  Ramiro Echeverry; Jialing Wu; Woldeab B Haile; Johanna Guzman; Manuel Yepes
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

Review 5.  Glutamate and the pathophysiology of hypoxic--ischemic brain damage.

Authors:  S M Rothman; J W Olney
Journal:  Ann Neurol       Date:  1986-02       Impact factor: 10.422

Review 6.  Structure and function of the NMDA receptor channel.

Authors:  H Mori; M Mishina
Journal:  Neuropharmacology       Date:  1995-10       Impact factor: 5.250

7.  Nuclear calcium signaling controls CREB-mediated gene expression triggered by synaptic activity.

Authors:  G E Hardingham; F J Arnold; H Bading
Journal:  Nat Neurosci       Date:  2001-03       Impact factor: 24.884

8.  A signaling cascade of nuclear calcium-CREB-ATF3 activated by synaptic NMDA receptors defines a gene repression module that protects against extrasynaptic NMDA receptor-induced neuronal cell death and ischemic brain damage.

Authors:  Sheng-Jia Zhang; Bettina Buchthal; David Lau; Stefanie Hayer; Oliver Dick; Markus Schwaninger; Roland Veltkamp; Ming Zou; Ursula Weiss; Hilmar Bading
Journal:  J Neurosci       Date:  2011-03-30       Impact factor: 6.167

9.  Ionic dependence of glutamate neurotoxicity.

Authors:  D W Choi
Journal:  J Neurosci       Date:  1987-02       Impact factor: 6.167

10.  Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. A plasminogen activator inhibitor type 1-independent t-PA receptor.

Authors:  G Bu; P A Morton; A L Schwartz
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

View more
  35 in total

1.  Tissue-type plasminogen activator mediates neuronal detection and adaptation to metabolic stress.

Authors:  Fang Wu; Andrew D Nicholson; Woldeab B Haile; Enrique Torre; Jie An; Changhua Chen; Andrew K Lee; Duc M Duong; Eric B Dammer; Nicholas T Seyfried; Frank C Tong; John R Votaw; Manuel Yepes
Journal:  J Cereb Blood Flow Metab       Date:  2013-07-24       Impact factor: 6.200

2.  Tissue-Type Plasminogen Activator-A296-299 Prevents Impairment of Cerebral Autoregulation After Stroke Through Lipoprotein-Related Receptor-Dependent Increase in cAMP and p38.

Authors:  William M Armstead; John Riley; Serge Yarovoi; Abd Al-Roof Higazi; Douglas B Cines
Journal:  Stroke       Date:  2016-06-28       Impact factor: 7.914

3.  Tissue-type plasminogen activator mediates neuroglial coupling in the central nervous system.

Authors:  J An; W B Haile; F Wu; E Torre; M Yepes
Journal:  Neuroscience       Date:  2013-11-04       Impact factor: 3.590

4.  LRP1 assembles unique co-receptor systems to initiate cell signaling in response to tissue-type plasminogen activator and myelin-associated glycoprotein.

Authors:  Elisabetta Mantuano; Michael S Lam; Steven L Gonias
Journal:  J Biol Chem       Date:  2013-10-15       Impact factor: 5.157

5.  Stressed neurons protect themselves by a tissue-type plasminogen activator-mediated EGFR-dependent mechanism.

Authors:  E Lemarchand; E Maubert; B Haelewyn; C Ali; M Rubio; D Vivien
Journal:  Cell Death Differ       Date:  2015-06-12       Impact factor: 15.828

6.  Subacute intranasal administration of tissue plasminogen activator improves stroke recovery by inducing axonal remodeling in mice.

Authors:  Ning Chen; Michael Chopp; Ye Xiong; Jian-Yong Qian; Mei Lu; Dong Zhou; Li He; Zhongwu Liu
Journal:  Exp Neurol       Date:  2018-03-05       Impact factor: 5.330

7.  Urokinase-type plasminogen activator promotes dendritic spine recovery and improves neurological outcome following ischemic stroke.

Authors:  Fang Wu; Marcela Catano; Ramiro Echeverry; Enrique Torre; Woldeab B Haile; Jie An; Changhua Chen; Lihong Cheng; Andrew Nicholson; Frank C Tong; Jaekeun Park; Manuel Yepes
Journal:  J Neurosci       Date:  2014-10-22       Impact factor: 6.167

8.  Tissue-type plasminogen activator triggers the synaptic vesicle cycle in cerebral cortical neurons.

Authors:  Fang Wu; Enrique Torre; David Cuellar-Giraldo; Lihong Cheng; Hong Yi; Edyta K Bichler; Paul S García; Manuel Yepes
Journal:  J Cereb Blood Flow Metab       Date:  2015-07-01       Impact factor: 6.200

9.  Novel link of anti-apoptotic ATF3 with pro-apoptotic CTMP in the ischemic brain.

Authors:  Chien-Yu Huang; Jin-Jer Chen; Jui-Sheng Wu; Hsin-Da Tsai; Heng Lin; Yu-Ting Yan; Chung Y Hsu; Yuan-Soon Ho; Teng-Nan Lin
Journal:  Mol Neurobiol       Date:  2014-04-26       Impact factor: 5.590

10.  Tissue-type plasminogen activator protects the postsynaptic density in the ischemic brain.

Authors:  Valerie Jeanneret; Juan P Ospina; Ariel Diaz; Luis G Manrique; Paola Merino; Laura Gutierrez; Enrique Torre; Fang Wu; Lihong Cheng; Manuel Yepes
Journal:  J Cereb Blood Flow Metab       Date:  2018-03-16       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.